Qsam Competitors

Delisted . USA . 
Stock . Qsam Biosciences
Qsam Biosciences competes with Lineage Cell, Cadrenal Therapeutics,, ImmuCell, Oxford Nanopore, and Fortress Biotech; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Qsam Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Qsam Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Qsam Biosciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Qsam Biosciences. Your research has to be compared to or analyzed against Qsam Biosciences' peers to derive any actionable benefits. When done correctly, Qsam Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Qsam Biosciences.

Qsam Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Qsam Biosciences and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Qsam and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Qsam Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
FBIOP
+ 0.79
ONTTF
CVKD
+ 0.67
LCTX
ICCC
+ 0.61
CVKD
AWKNF
+ 0.36
ONTTF
ICCC
+ 0.35
LCTX
AWKNF
+ 0.13
FBIOP
  
High negative correlations   
ONTTF
- 0.41
CVKD
AWKNF
- 0.4
CVKD
FBIOP
- 0.31
CVKD
AWKNF
- 0.22
ICCC
ONTTF
- 0.16
ICCC
AWKNF
- 0.06
LCTX

Risk-Adjusted Indicators

There is a big difference between Qsam OTC Stock performing well and Qsam Biosciences OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Qsam Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
AGE  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
LCTX  4.06  0.22  0.05  0.25  4.39 
(6.24)
 12.00 
(8.62)
 24.78 
CVKD  4.32  0.74  0.14  0.62  4.67 
(5.20)
 11.59 
(8.49)
 25.08 
ICCC  3.27  0.12  0.04  0.05  4.10 
(3.41)
 6.85 
(7.04)
 16.94 
ONTTF  3.76 (0.28) 0.00 (0.28) 0.00 
 0.00 
 6.98 
(8.29)
 25.80 
ARDS  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MSSTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
FBIOP  2.58 (0.22) 0.00  0.07  0.00 
 0.00 
 7.27 
(4.44)
 15.52 
AWKNF  0.55 (0.19) 0.00 (16.21) 0.00 
 0.00 
 0.00 
 0.00 
 24.71 
RGRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Qsam Biosciences Competitive Analysis

The better you understand Qsam Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Qsam Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Qsam Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LCTX CVKD ICCC ONTTF FBIOP AWKNF HSTO PMVP ENLV APVO
 1.89 
 0.52 
Lineage
 1.25 
 17.45 
Cadrenal
 1.87 
 4.89 
ImmuCell
 0.78 
 1.30 
Oxford
 3.83 
 6.50 
Fortress
 0.00 
 0.07 
Awakn
 0.00 
 0.03 
Histogen
 1.59 
 1.24 
Pmv
 9.17 
 1.09 
Enlivex
 0.83 
 2.38 
Aptevo
Market Volatility
(90 Days Market Risk)
Dangerous
Somewhat reliable
Slightly risky
Dangerous
Slightly risky
Very steady
Out of control
Unstable
Risky
Very risky
Market Performance
(90 Days Performance)
Insignificant
Good
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Below Average
Quite High
Above Average
Very High
Dangerous
Low
Low
Very High
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Strong Buy
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Hold
Hold
Hold
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Hold
Strong Hold
Strong Sell
Current Ratio
3.01
N/A
6.91
8.51
2.85
0.46
13.22
24.76
15.44
4.48
Net Asset
113.22 M
8.52 M
43.81 M
841.87 M
396.5 M
6.88 M
19.07 M
191.29 M
36.83 M
15.59 M
Profit Margin
-1.96
N/A
-0.17
-0.78
-1.17
N/A
N/A
N/A
N/A
N/A
EBITDA
(21.48 M)
(8.34 M)
(2.5 M)
(140.41 M)
(46.05 M)
(16.08 M)
(11.92 M)
(85.45 M)
(28.22 M)
(24.6 M)
Current Valuation
73.5 M
25.35 M
54.5 M
1.7 B
2.58 B
6.58 M
(4.46 M)
(103.87 M)
1.77 M
(322.21 K)
Price To Book
1.52
8.71
1.55
2.69
N/A
4.19
0.0212
0.37
0.96
0.79
Operating Margin
-1.78
N/A
-0.25
-0.72
-2.63
-8.79
-705.0
N/A
N/A
N/A
Retained Earnings
(403.46 M)
(15.07 M)
(12.01 M)
N/A
N/A
N/A
(88.27 M)
(368.71 M)
(112.09 M)
(247.58 M)
Current Asset
12.84 M
N/A
4.49 M
N/A
N/A
N/A
N/A
N/A
6 M
71.41 M
Beta
1.28
1.45
0.57
N/A
1.9
N/A
1.12
1.45
1.11
5.24
Number Of Employees
70
4
N/A
900
173
43
7
47
N/A
37
Shares Outstanding
228.36 M
1.78 M
8.91 M
825.96 M
56.68 M
32.48 M
4.27 M
51.93 M
21.99 M
1.46 M
Cash Flow From Operations
(23.09 M)
(3.53 M)
(4.67 M)
(53.83 M)
(116.54 M)
(8.59 M)
(10.07 M)
(51.28 M)
(23.52 M)
(23.79 M)
Annual Yield
N/A
N/A
N/A
N/A
0.12
N/A
N/A
N/A
N/A
N/A
Total Debt
2.51 M
21.35 K
16.69 M
9.5 M
46.56 M
1.62 M
4.63 M
1.19 M
1.03 M
4.63 M
Return On Equity
-0.27
-1.25
-0.16
-0.28
-1.43
-2.84
-1.2
-0.29
-0.58
-2.84
Z Score
N/A
N/A
N/A
N/A
1.2
-1.8
N/A
N/A
N/A
N/A
Return On Asset
-0.13
-0.71
-0.0487
-0.14
-0.35
-0.82
-0.54
-0.24
-0.26
-0.76
Book Value Per Share
0.36
2.76
3.23
0.88
0.57
0.064
1.27
3.39
1.21
3.26
Number Of Shares Shorted
22.03 M
41.48 K
18.25 K
N/A
245
N/A
67.03 K
864.66 K
105.11 K
23.49 K
Current Liabilities
2.74 M
N/A
258.78 K
N/A
N/A
N/A
N/A
N/A
671.32 K
19.54 M
Total Asset
113.22 M
8.52 M
43.81 M
841.87 M
396.5 M
6.88 M
19.07 M
191.29 M
36.83 M
15.59 M
Debt To Equity
0.036
N/A
0.36
0.033
0.81
1.13
0.31
0.045
0.077
0.47
Short Ratio
18.69
0.71
0.23
N/A
0.02
N/A
4.25
8.38
1.73
1.45
Target Price
4.33
35.67
14.0
N/A
N/A
10.04
2.0
6.0
9.5
21.0
Shares Owned By Institutions
53.91
5.95
14.51
40.78
1.8
8.34
N/A
81.35
22.15
4.84
Market Capitalization
118.79 M
31.5 M
32.08 M
2.3 B
107.79 M
13.25 M
85.44 K
65.44 M
26.39 M
3.5 M
Price To Earning
3.62
N/A
195.0
N/A
N/A
N/A
N/A
N/A
-11.97
2.48
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
-0.04
-0.31
N/A
N/A
Price To Sales
12.51
N/A
1.61
12.58
1.36
7.96
4.5
N/A
N/A
1.61
Net Income
(18.61 M)
(8.36 M)
(5.77 M)
(167.61 M)
(164.83 M)
(15.95 M)
(12.38 M)
(58.71 M)
(29.07 M)
(24.13 M)
Earnings Per Share
-0.09
-6.73
-0.49
-0.28
-0.86
-0.56
-2.81
-1.14
-0.98
-87.38
Shares Owned By Insiders
0.55
32.37
39.52
34.06
N/A
9.92
2.85
2.48
5.59
0.011
Revenue
9.5 M
N/A
17.47 M
133.66 M
68.79 M
236.04 K
19 K
N/A
N/A
N/A
Working Capital
37.02 M
7.67 M
10.92 M
N/A
N/A
N/A
12.22 M
161.29 M
27.7 M
4.45 M
Cash And Equivalents
66.36 M
N/A
11.04 M
471.65 M
248.77 M
481.83 K
12.6 M
277.43 M
62.48 M
29.43 M
Cash Per Share
0.39
N/A
1.43
0.57
2.31
0.02
5.04
6.08
3.4
5.78
Gross Profit
(3.31 M)
N/A
7.65 B
73.19 M
(85.66 M)
(276.83 K)
(3.26 M)
N/A
N/A
(302 K)
Day Typical Price
0.53
17.32
4.71
1.3
6.4
0.065
0.027
1.25
1.13
2.41
Accumulation Distribution
0.0545
2254.0
2095.54
N/A
0.0446
N/A
N/A
1292.44
15848.72
535.37
Market Facilitation Index
0.03
1.0E-4
0.0
N/A
0.29
N/A
N/A
0.0
0.0
0.0
Daily Balance Of Power
(0.33)
(0.15)
0.1343
9.2 T
0.8276
0.0
0.0
(0.50)
(0.69)
(0.14)
Period Momentum Indicator
(0.01)
(0.22)
0.09
0.01
0.24
N/A
N/A
(0.02)
(0.11)
(0.02)
Rate Of Daily Change
0.98
0.99
1.02
1.01
1.04
1.0
1.0
0.98
0.91
0.99
Day Median Price
0.54
17.25
4.62
1.3
6.36
0.065
0.027
1.25
1.15
2.42
Price Action Indicator
(0.02)
0.09
0.32
0.005
0.27
N/A
N/A
(0.02)
(0.11)
(0.05)
Coefficient Of Variation
3627.35
910.4
10164.98
(971.67)
(5,107)
(1,306)
(951.16)
(641.69)
(8,649)
(469.46)
Mean Deviation
4.06
4.32
3.27
3.76
2.58
0.5533
5.31
1.85
2.55
5.16
Jensen Alpha
0.2217
0.7393
0.1164
(0.28)
(0.22)
(0.19)
(1.74)
(0.27)
0.0983
(1.67)
Total Risk Alpha
1.01
1.48
0.6591
0.2329
0.4649
0.1726
0.6215
(0.02)
0.5432
(0.50)
Sortino Ratio
0.0518
0.1401
0.0371
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
27.83
27.9
17.95
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
5.69
5.67
4.12
4.91
3.58
2.41
13.37
2.58
3.93
8.16
Kurtosis
1.09
0.259
(0.30)
1.31
3.76
53.42
29.24
2.96
6.6
11.15
Potential Upside
12.0
11.59
6.85
6.98
7.27
N/A
10.8
4.41
5.88
8.25
Treynor Ratio
0.2482
0.6155
0.0451
(0.28)
0.0713
(16.21)
0.5551
(0.37)
(0.05)
(2.69)
Maximum Drawdown
24.78
25.08
16.94
25.8
15.52
24.71
93.31
16.42
31.5
52.56
Variance
32.33
32.18
17.01
24.11
12.79
5.8
178.73
6.65
15.44
66.57
Market Risk Adjusted Performance
0.2582
0.6255
0.0551
(0.27)
0.0813
(16.20)
0.5651
(0.36)
(0.04)
(2.68)
Risk Adjusted Performance
0.0315
0.0999
0.0162
(0.08)
(0.01)
(0.06)
(0.08)
(0.12)
(0)
(0.17)
Skewness
0.5223
0.2018
(0.11)
0.2841
1.17
(6.60)
(4.19)
(0.30)
0.3896
(2.58)
Semi Deviation
4.39
4.67
4.1
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.0481
0.1304
0.0381
(0.08)
0.0131
(0.03)
(0.1)
(0.11)
0.0181
(0.20)
Value At Risk
(8.62)
(8.49)
(7.04)
(8.29)
(4.44)
N/A
(10.71)
(3.65)
(5.60)
(10.00)
Expected Short fall
(6.24)
(5.20)
(3.41)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
5.28
5.28
4.24
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
19.25
21.85
16.82
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Qsam Biosciences Competition Performance Charts

Five steps to successful analysis of Qsam Biosciences Competition

Qsam Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Qsam Biosciences in relation to its competition. Qsam Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Qsam Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Qsam Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Qsam Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Qsam Biosciences position

In addition to having Qsam Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Giant Impact Thematic Idea Now

Giant Impact
Giant Impact Theme
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation.
Note that the Qsam Biosciences information on this page should be used as a complementary analysis to other Qsam Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Qsam OTC Stock

If you are still planning to invest in Qsam Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Qsam Biosciences' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Commodity Directory
Find actively traded commodities issued by global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY